Cystic fibrosis: a clinical view

Cellular and Molecular Life Sciences

Volumn 74, Issue 1, 2017, Pages 129-140

  Castellani, Carlo ^a   Assael, Baroukh M ^b  

^a Cystic Fibrosis Center   (Italy)

^b Regional Cystic Fibrosis Centre   (Italy)

Author keywords

CFTR; Cystic fibrosis; Genotype; Phenotype; Precision medicine

Indexed keywords

4 PHENYLBUTYRIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMITRIPTYLINE; ANTIBIOTIC AGENT; ATALUREN; CORTICOSTEROID; CURCUMIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENUFOSOL; GENISTEIN; GLUTATHIONE; IBUPROFEN; IVACAFTOR; MACROLIDE; MUCOLYTIC AGENT; PANCREAS ENZYME; RESVERATROL; ROSCOVITINE; TOBRAMYCIN;

ADOLESCENCE; ADULTHOOD; BONE DISEASE; BRONCHIECTASIS; CALORIC RESTRICTION; CHROMOSOME 7; CHRONIC SINUSITIS; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EAR NOSE THROAT SURGERY; EARLY DIAGNOSIS; ENTEROPATHY; ENZYME REPLACEMENT; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; GROWTH RETARDATION; HUMAN; HYPOPROTEINEMIA; INTESTINE CANCER; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG DISEASE; LUNG INFECTION; LUNG INJURY; LUNG TRANSPLANTATION; MALABSORPTION; MALE INFERTILITY; MODIFIER GENE; MUCOCELE; MUTATIONAL ANALYSIS; NEWBORN SCREENING; NOSE POLYP; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS DISEASE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRENATAL DIAGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSEUDOMONAS INFECTION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SURVIVAL TIME; GENETICS; GENOTYPE; LUNG; METABOLISM; MUTATION; PANCREAS; PATHOLOGY; PROCEDURES;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EARLY DIAGNOSIS; GENETIC THERAPY; GENOTYPE; HUMANS; LUNG; MUTATION; PANCREAS; PRECISION MEDICINE; PRENATAL DIAGNOSIS;

EID: 84990855968     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2393-9     Document Type: Review

References (126)

1. Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 56:344–399
2. http://www.cysticfibrosis.ca/. Accessed 1 Aug 2016
3. Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR (2014) Rate of improvement of CF life expectancy exceeds that of general population–observational death registration study. J Cyst Fibros 13:410–415
4. Burgel P-R, Bellis G, Olesen H, Viviani L, Zolin A, Blasi F, Elborn JS (2015) Future trends in cystic fibrosis demography in 34 European countries. Euro Respir J 46:133–141
5. Plant BJ, Goss CH, Plant WD, Bell SC (2013) Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 1:164–174
6. Gadsby DC, Vergani P, Csanády L (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440:477–483
7. Keiser NW, Engelhardt JF (2011) New animal models of cystic fibrosis: what are they teaching us? Curr Opin Pulm Med 17:478–483
8. Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A, Meyerovitch J, Sher D, Assael BM (2013) Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros 12:165–169
9. Jin R, Hodges CA, Drumm ML, Palmert MR (2006) The cystic fibrosis transmembrane conductance regulator (CFTR) modulates the timing of puberty in mice. J Med Genet 43:e29
10. Delion M, Braux J, Jourdain ML, Guillaume C, Bour C, Gangloff S, Le Pimpec-Barthes F, Sermet-Gaudelus I, Jacquot J, Velard F (2016) Over-expression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis. J Pathol. doi:10.1002/path.4753
11. Gibney EM, Goldfarb DS (2003) The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis 42:1–11
12. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB (2013) Cancer risk in cystic Fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst 105:122–129
13. Billings JL, Dunitz JM, McAllister S, Herzog T, Bobr A, Khoruts A (2014) Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol 48:e85–e88
14. Azimi A (2015) Cystic fibrosis could survive cholera, choleraics could survive cystic fibrosis, hypothesis that explores new horizon in treatmnet of cystic fibrosis. Med Hypoth 85:715–717
15. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N et al (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1065
16. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–1080
17. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073
18. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45:1160–1167
19. Tsui LC (1992) The spectrum of cystic fibrosis mutations. Trends Genet 8:392–398
20. Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251–1254
21. Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29:777–807
22. Bombieri C, Seia M, Castellani C (2015) Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator-Related DisordersSemin Respir. Crit Care Med 36:1–14
23. Andersen DH (1958) Cystic fibrosis of the pancreas. J Chronic Dis 7:58–90
24. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C (2011) Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 10(Suppl 2):S86–S102
25. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR, Gene Modifier Study Group (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443–1453
26. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C (1982) Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis. 125:409–415
27. McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R (1994) Genetic and environmental influences on pulmonary function in aging Swedish twins. J Gerontol. 49:264–268
28. Tümmler B., Stanke F. (2014) Genetic and environmental modifiers of cystic fibrosis. In: Mall MA, Elborn JS (eds) Cystic fibrosis. ERS Monographs
29. Knowles MR, Drumm M. (2012) The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med 2(12):a009548
30. Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H (2004) Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 41:629–633
31. Hillian AD, Londono D, Dunn JM, Goddard KAB, Pace RG, Knowles MR, Drumm ML, CF Gene Modifier Study Group (2008) Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 9:501–508
32. Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, Assael BM, Badolato R (2010) PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 11:665–670
33. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM et al (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539–546
34. Green DM, Collaco JM, McDougal KE, Naughton KM, Blackman SM, Cutting GR (2012) Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J Pediatr 161:290–295
35. Khan TZ, Wagener JS, Bost T, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075–1082
36. Schultz A, Stick S (2015) Early pulmonary inflammation and lung damage in children with cystic fibrosis. Respirology 20:569–578
37. Cohen TS, Prince A (2012) Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18:509–519
38. Sorio C, Montresor A, Bolomini-Vittori M, Caldrer S, Rossi B, Dusi S, Angiari S, Johansson JE, Vezzalini M, Leal T, Calcaterra E, Assael BM, Melotti P, Laudanna C (2016) Mutations of cystic fibrosis transmembrane conductance regulator gene cause a monocyte-selective adhesion deficiency. Am J Respir Crit Care Med 193:1123–1133
39. Grabiec AM, Hussell T (2016) The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin Immunopathol. 38:409–423
40. Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY (2012) Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012:948367
41. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd (2008) Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4–S14
42. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M, on behalf of the Diagnostic Working Group (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635
43. Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential techniques and protocols for the assessment of the efficiency of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455
44. De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tümmler B, Sinaasappel M (2004) Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 3:159–163
45. De Oronzo MA (2011) Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome? J Prenatal Med 5:9–13
46. Castellani C, Massie J, Sontag M, Southern KW (2016) Newborn screening for cystic fibrosis. Lancet Respir Med. doi:10.1016/S2213-2600(16)00053-9
47. Quinton P (2006) Cystic fibrosis: lessons from the sweat gland. Physiology 22:212–225
48. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, Investigators ARESTCF (2013) Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368:1963–1970
49. Sly PD, Brennan S (2004) Detecting early lung disease in cystic fibrosis: are current techniques sufficient? Thorax 59:1008–1010
50. Tiddens HA (2002) Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 34:228–231
51. Mott LS, Graniel KG, Park J, de Klerk NH, Sly PD, Murray CP, Tiddens HA, Stephen MS, Arest CF (2013) Assessment of early bronchiectasis in young children with cystic fibrosis is dependent on lung volume. Chest 144:1193–1198
52. Simpson SJ, Ranganathan S, Park J, Turkovic L, Robins-Browne RM, Skoric B, Ramsey KA, Rosenow T, Banton GL, Berry L, Stick SM, Hall GL, Arest CF (2015) Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection. Eur Respir J 46:1680–1690
53. Tang AC, Turvey SE, Alves MP, Regamey N, Tümmler B, Hartl D (2014) Current concepts: host-pathogen interactions in cystic fibrosis airways disease. Eur Respir Rev 23:320–332
54. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Bánfi B, Horswill AR, Stoltz DA, McCray PB Jr, Welsh MJ, Zabner J (2012) Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487:109–113
55. Huang YJ, LiPuma JJ (2016) The Microbiome in Cystic Fibrosis. Clin Chest Med 37:59–67
56. Justicia JL, Solé A, Quintana-Gallego E, Gartner S, de Gracia J, Prados C, Máiz L (2015) Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice. Expert Rev Respir Med. 9:183–194
57. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 1:461–479
58. Stenbit AE, Flume PA (2011) Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 17:442–447
59. Walter S, Gudowius P, Bosshammer J, Römling U, Weissbrodt H, Schürmann W, von der Hardt H, Tümmler B (1997) Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 52:318–321
60. Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aanæs K, von Buchwald C, Høiby N, Molin S (2012) Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 6:31–45
61. Illing EA, Woodworth BA (2014) Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med. 20:623–631
62. De Lisle RC, Borowitz D (2013) The Cystic Fibrosis Intestine. Cold Spring Harb Perspect Med 3:a009753
63. Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, Gruca M, Tamanini A, Assael MB, Gaskin K (2007) Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child 92:842–846
64. Daftary A, Acton J, Heubi J, Amin R (2006) Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros 5:71–76
65. Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, Gonska T (2016) Prevalence of meconium ileus marks the severity of mutations of the cystic fibrosistransmembrane conductance regulator (CFTR) gene. Genet Med 18:333–340
66. Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, Auricchio S, Londei M (2000) Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 47:344–350
67. Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR, Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E (2016) Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis. Sci Rep. 6:22493
68. Munck A (2014) Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 52:180–183
69. Flass T, Narkewicz MR (2013) Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 12:116–124
70. Castaldo G, Fuccio A, Salvatore D, Raia V, Santostasi T, Leonardi S, Lizzi N, La Rosa M, Rigillo N, Salvatore F (2001) Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. Am J Med Genet 98:294–297
71. Pereira TN, Lewindon PJ, Greer RM, Hoskins AC, Williamson RM, Shepherd RW, Ramm GA (2012) Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease. J Pediatr Gastroenterol Nutr 54:328–335
72. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, Gene Modifier Study Group (2009) Genetic modifiers of liver disease in cystic fibrosis. JAMA 302:1076–1083
73. Kelly A, Moran A (2013) Update on cystic fibrosis-related diabetes. J Cyst Fibros 12:318–331. doi:10.1016/j.jcf.2013.02.008 (Erratum. In: J Cyst Fibros. 2014;13:119)
74. Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE, Conway SP, Castanet M, Wolfe S, Haworth CS (2011) European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 10(Suppl 2):S16–S23
75. Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Caminiti M, Brown SA, Renner JB, Chalermskulrat W, Lester GE (2002) Osteoporos Int 13(2):151–157
76. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE (2007) Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62:650–651
77. Yu J, Chen Z, Ni Y, Li Z (2012) CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum Reprod 27:25–35
78. Quinzii C, Castellani C (2000) The cystic fibrosis transmembrane regulator gene and male infertility. J Endocrinol Invest 23:684–689
79. Assael BM, Casazza G, Iansa P, Volpi S, Milani S (2009) Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol 44:209–215
80. Rogan MP, Reznikov LR, Pezzulo AA, Gansemer ND, Samuel M, Prather RS, Zabner J, Fredericks DC, McCray PB Jr, Welsh MJ, Stoltz DA (2010) Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci U S A. 107:20571–20575
81. Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D (2014) European Cystic Fibrosis Society Standards of Care: framework for the Cystic Fibrosis Centre. J Cyst Fibros 13(Suppl 1):S3–S22
82. Corey M, McLaughlin FJ, Williams M, Levison H (1988) A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41:583–591
83. Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S, Schneider SM, Wilschanski M (2016) ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 35:557–577
84. Maqbool A, Schall JI, Gallagher PR, Zemel BS, Strandvik B, Stallings VA (2012) Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 55:605–611
85. Strandvik B (2010) Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 83:121–129
86. Maqbool A, Schall JI, Garcia-Espana JF, Zemel BS, Strandvik B, Stallings VA (2008) Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 4:635–644
87. van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM (1996) Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 63:746–752
88. Morrell MR, Pilewski JM (2016) Lung transplantation for cystic fibrosis. Clin Chest Med 37:127–138
89. Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS (2015) Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med. 36:299–320
90. Leeuwen L, Fitzgerald DA, Gaskin KJ (2014) Liver disease in cystic fibrosis. Paediatr Respir Rev 15:69–74
91. Hughes A, Adil EA (2015) What is the role of endoscopic sinus surgery in adult patients with cystic fibrosis? Laryngoscope 125:2018–2020
92. Lands LC, Milner R, Cantin AM, Manson D, Corey M (2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151:249–254
93. Spagnolo P, Fabbri LM, Bush A (2013) Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42:239–251
94. Southern KW, Barker PM, Solis-Moya A, Patel L (2012) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 11:CD002203
95. Lee TW, Southern KW, Perry LA, Penny-Dimri JC, Aslam AA (2016) Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst Rev 17:CD005599. doi:10.1002/14651858.CD005599.pub5
96. Oakland M, Sinn PL, McCray PB Jr (2012) Advances in cell and gene-based therapies for cystic fi brosis lung disease. Mol Ther 20:1108–1115
97. Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DD, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JS, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P, UK Cystic Fibrosis Gene Therapy Consortium (2015) Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 3:684–691
98. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6:119–126
99. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, van Koningsbruggen-Rietschel S, Staab D, Rolinck-Werninghaus C, Mellies U, Köhnlein T, Wagner T, König S, Teschler H, Heuer HE, Kopp M, Heyder S, Hammermann J, Küster P, Honer M, Mansmann U, Beck-Speier I, Hartl D, Fuchs C, Glutathione Study Group, Hector A (2013) Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 188:83–89
100. Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, Heyder S, Gulbins E, Riethmueller J (2016) Long-Term Pulmonal Therapy of Cystic Fibrosis-Patients with Amitriptyline. Cell Physiol Biochem 39:565–572
101. Nährlich L, Mainz JG, Adams C, Engel C, Herrmann G, Icheva V, Lauer J, Deppisch C, Wirth A, Unger K, Graepler-Mainka U, Hector A, Heyder S, Stern M, Döring G, Gulbins E, Riethmüller J (2013) Therapy of CF-patients with amitriptyline and placebo–a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 31:505–512
102. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42:716–724
103. Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24:65–72
104. Dey I, Shah K, Bradbury NA (2016) Natural Compounds as Therapeutic Agents in the Treatment Cystic Fibrosis. J Genet Syndr Gene Ther 7pii: 284
105. Moss RB (2013) Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162:676–680
106. ClinicalTrials.gov Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF) Last verified July 2016
107. Fayon M, Kent L, Bui S, Dupont L, Sermet I (2014) European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee. Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis. Eur Respir J 43:610–626
108. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860–865
109. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433–1441
110. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182:1262–1272
111. De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, Middleton P, de Jonge H, Bronsveld I, Wilschanski M, Melotti P, Danner-Boucher I, Boerner S, Fajac I, Southern K, de Nooijer RA, Bot A, de Rijke Y, de Wachter E, Leal T, Vermeulen F, Hug MJ, Rault G, Nguyen-Khoa T, Barreto C, Proesmans M, Sermet-Gaudelus I, European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee (2013) CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 4:203–216
112. Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM (2016) Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med 8:344ra84
113. Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Beekman JM (2016) Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations. J Cyst Fibros. doi:10.1016/j.jcf.2016.04.007
114. Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM (2016) Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. doi:10.1183/13993003.01192-2015
115. Vidović D, Carlon MS, da Cunha MF, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z (2016) rAAV-CFTRΔR Rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice. Am J Respir Crit Care Med 193:288–298
116. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2:539–547
117. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663–1672
118. Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J (2014) Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 18:1–106
119. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group (2015) Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 3:524–533
120. De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M (2014) Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13:674–680
121. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group (2015) Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373:220–231
122. https://www.cff.org/Trials/pipeline. Accessed 1 Aug 2016
123. De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, Maiuri MC, Pettoello-Mantovani M, Guido S, Bossi A, Zolin A, Venerando A, Pinna LA, Mehta A, Bona G, Kroemer G, Maiuri L, Raia V (2014) Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 10:2053–2074
124. Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA, Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V (2016) A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ 23:1380–1393
125. Hoffman LR, Ramsey BW (2013) Cystic fibrosis therapeutics: the road ahead. Chest 143:207–213
126. Davis PB (2011) Therapy for cystic fibrosis—the end of the beginning? N Engl J Med 365:1734–1735